OSLO, NORWAY – 15 August 2024: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces the launch of a microbiome research product for Luminex xMAP® users globally. The GA-map® Discovery reagent kit will offer high-volume precision microbiome analysis to research customers in academia and the pharmaceutical industry. This market is currently witnessing considerable growth, and through this launch, GA will strengthen its position as a pioneer in the microbiome analysis field.
As communicated on October 24, 2023, GA launched the GA-map® Discovery service from its lab in Oslo to research customers within academia and the pharmaceutical industry. Since then, GA has further developed the product, and it is now available as a reagent kit to be used by research labs worldwide. Built on the standardised GA-map® platform, GA-map® Discovery offers comprehensive gut and oral microbiome profiling. The GA-map® platform utilises the unique Luminex xMAP® technology allowing targeted and effective detection of multiple targets simultaneously.
Comprising more than 170 bacteria targets, GA-map® Discovery provides researchers a much-needed tool to search for bacteria profiles / signatures associated with health and disease, as well as validate exploratory research findings. With this launch, GA brings to the market a reagent kit with high accuracy, exceptional reproducibility, and short turnaround time, enabling cost-effective microbiome profiling for the lab.
Sherry Dunbar, Senior Director of Scientific Affairs Programs for Luminex Corp., comments:
“We are excited to see the launch of new products based on Luminex’s xMAP® Technology. This product skillfully combines the high-plex capability of xMAP Technology with GA’s unique method for detection and quantification of microbiome targets. The GA-map® Discovery assay will provide exciting opportunities for accessible microbiome analyses to both new and existing Luminex users worldwide.”
Ronny Hermansen, CEO of Genetic Analysis, comments:
“We are thrilled to introduce the GA-map® Discovery, our latest advancement in microbiome research. This innovative product further solidifies GA’s position in microbiome research, providing an unparalleled tool for both academia and industry. With the microbiome being one of the hottest research areas in clinical medicine and life science today, this high-plex microbiome panel will facilitate researchers in their quest to harness the power of the microbiome.”
About the Microbiome research market
The composition of the microbiome, the microorganisms that live in and on our bodies, has been linked to gastrointestinal disorders, inflammation, autoimmune disease, neurodegenerative and psychological disorders, and more. In recent years, microbiome research has fueled new inventions in diagnostics, therapeutics, and in disease prevention. The microbiome research market was valued at $859 million in 2021 and is projected to reach $3,417 million by 2031 (1).
For further information, please contact:
Ronny Hermansen, Chief Executive Officer
E-mail: rh@genetic-analysis.com
About Genetic Analysis:
Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 15 years of expertise in research and product development. The unique GA-map® platform is based on a pre-determined multiplex targets approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. GA’s vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA employs a team of highly qualified employees with scientific backgrounds and competence in bioinformatics, molecular biology, and bioengineering.
For more general information: www.genetic-analysis.com
Stay updated on GA and sign up for more investor-related information: https://www.genetic-analysis.com/subscriptions/
Interested in reading more about GA's products? Please visit ga-map.com